At 4TEEN4 we are researching diseases related to circulating dipeptidyl peptidase 3 (DPP3), a biomarker and target for our therapeutic antibody Procizumab.
Location: Germany, Brandenburg, Hennigsdorf
Total raised: $8.43M
Investors 1
| Date | Name | Website |
| - | BFB Brande... | brandenbur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| - | Series A | $8.43M | - |
Mentions in press and media 4
| Date | Title | Description |
| 11.04.2022 | Dipeptidyl Peptidase 3 Biomarker to Drive Precision Medicine in COVID-19 | Dipeptidyl Peptidase 3 release is a fatal clinical pathway in severe COVID-19 patients resulting in organ dysfunction and short-term mortality New COVID-19 trial conducted by University Hospital Hamburg-Eppendorf is implementing a biomarker... |
| 01.12.2021 | 4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab | AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The fir... |
| 25.03.2021 | 4TEEN4 Pharmaceuticals GmbH: DPP3 predicts organ failure and in-hospital mortality in post-operative patients | DGAP-News: 4TEEN4 Pharmaceuticals GmbH / Key word(s): Study/Study results 4TEEN4 Pharmaceuticals GmbH: DPP3 predicts organ failure and in-hospital mortality in post-operative patients 25.03.2021 / 10:00 The issuer is solely responsible for ... |
| - | Biotech Startup 4TEEN4 Pharmaceuticals Closes EUR 7 Million Series A Financing | Hennigsdorf/Berlin, Germany, December, 2019 – 4TEEN4 Pharmaceuticals GmbH (formerly Sphingotec Therapeutics GmbH) announced today the closing of a EUR 6.9 million Series A financing round. The new funds will be used to advance the preclinic... |